Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed / Refractory B-precursor Acute Lymphoblastic Leukemia
Pediatric Leukemia
Pediatric Leukemia
The primary objectives of this study are to evaluate the safety and efficacy of KTE-C19 in pediatric and adolescent participants with relapsed / refractory (r / r) B-precursor acute lymphoblastic leukemia (ALL).
Pediatric Leukemia
I/II
Kitko, Carrie
NCT02625480
VICCPED15143
A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies
Sickle Cell
Sickle Cell
Sickle Cell
N/A
Kassim, Adetola
NCT01850108
VICCNCBMT12108
HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, TBI and Fludarabine; Postgrafting Immunosuppression will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus
Not Available
N/A
Connelly, James
NCT00358657
VICCNCPED1414
Standard Chemotherapy in Treating Young Patients with Medulloblastoma or Other Central Nervous System Primitive Neuro-ectodermal Tumors
Neuroblastoma (Pediatrics)
Neuroblastoma (Pediatrics)
This phase IV trial studies how well standard chemotherapy works in treating young patients with medulloblastoma or other central nervous system primitive neuro-ectodermal tumors. Drugs used in standard chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Neuroblastoma (Pediatrics)
IV
Esbenshade, Adam
NCT02875314
VICCPED1751
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed / Refractory Indolent Non-Hodgkin Lymphoma
Lymphoma
Lymphoma
This study will enroll approximately 160 adult subjects who have relapsed or refractory (r / r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is made from the subjects own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70% is targeted.
Lymphoma
II
Oluwole, Olalekan
NCT03105336
VICCBMT1844
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
Multiple Cancer Types
This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better compared to crizotinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Neuroblastoma (Pediatrics),
Pediatrics
III
Kitko, Carrie
NCT03126916
COGANBL1531
